137417-08-4

Usage

Uses

Used in Pharmaceutical Industry:
(±)-trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride is used as a pharmaceutical agent for its antiviral, anti-inflammatory, and anticancer properties. It is being studied for its potential to treat various diseases and conditions, including cancer and neurological disorders.
Used in Neuroscience Research:
In the field of neuroscience, (±)-trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine hydrochloride is used as a research tool to explore its potential in treating neurological disorders. Its diverse pharmacological activities make it a valuable compound for understanding the underlying mechanisms of these conditions and developing new therapeutic approaches.

Upstream product

• 126295-91-8 dihydrexidine 
• 174691-84-0 dihydrexidine 
• 406174-96-7 N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-methoxymethyl-4-methyl-benzenesulfonamide 
• 1315338-46-5 (1R,2R)-N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-N-methoxymethyl-4-nitro-benzenesulfonamide 
• 1315338-50-1 (6aR,12bS)-10,11-dimethoxy-6-(4-nitrobenzenesulfonyl)-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine 
• 1315338-44-3 (1R,2R)-N-(6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydro-naphthalen-2-yl)-4-nitro-benzenesulfonamide 
• 85185-33-7 1,2-dimethoxy-4-(4-phenyl-but-3-enyl)benzene 
• 406499-03-4 (6aR,12bS)-(+)-10,11-dimethoxy-5,6,6a,7,8,12b-hexahydrobenzophenanthridine 
• 1345820-59-8 [(R)-1-[(R)-(tert-butyldimethylsilanyloxy)(phenyl)methyl]-3-(3,4-dimethoxyphenyl)propyl]carbamic acid tert-butyl ester 
• 1345820-58-7 [(R)-1-[(R)-(tert-butyldimethylsilanyloxy)phenylmethyl]-3-(3,4-dimethoxyphenyl)allyl]carbamic acid tert-butyl ester 
• 1345820-54-3 [(R)-3-(3,4-dimethoxyphenyl)-1-(R)-(hydroxy(phenyl)methyl)propyl]carbamic acid tert-butyl ester 
• 406174-91-2 (1R,2R)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylamine 
• 123039-93-0 (6a,12b)-trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine 

Relevant academic research and scientific papers

Asymmetric synthesis of the dopamine D1 agonist, dihydrexidine

A concise asymmetric synthesis of first, high affinity domaine D1 full agonist, dihydrexidine has been accomplished via catalytic enantioselective aziridination and subsequent one-pot Friedel-Crafts cyclization of an in situ generated tethered aziridine w

Asymmetric synthesis of a dopamine D1 agonist, dihydrexidine from d-serine

A scalable asymmetric synthesis of trans-2-amino-6,7-dimethoxy-1- phenyltetralin 2 and its N-nosyl derivative 12 have been achieved from Garner aldehyde derived from easily available d-serine using a stereoselective PhMgBr addition, Wittig reaction and TF

A novel and efficient synthesis of dihydrexidine

An efficient synthesis of the dopamine D1 selective full agonist dihydrexidine has been achieved in high yields and requiring no chromatographic separations via a facilitated intramolecular Henry cyclization of a (nitropropyl)benzophenone and subsequent diastereomerically selective reduction of the resulting tricyclic ni- troalkene. Georg Thieme Verlag Stuttgart.

Co-administration of dopamine-receptor binding compounds

Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D1 receptor agonist, and administering to the patient an effective amount of a dopamine D2 receptor antagonist. Pharmaceutical compositions comprising a dopamine D1 receptor agonist and a dopamine D2 receptor antagonist are also described. The D1 dopamine receptor agonist and the D2 dopamine receptor antagonist can be administered to the patient in the same or in a different composition or compositions.

METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS

Methods for treating a patient having pulmonary edema are described. The methods include administering to the lung endobronchial space of the airways of the patient an effective amount of a dopamine D1 receptor agonist. Dopamine D1 receptor agonists, including hexahydrobenzophenanthridine, hexahydrothienophenanthridine, phenylbenzodiazepine, chromenoisoquinoline, naphthoisoquinoline dopamine receptor agonists, and their pharmaceutically acceptable salts, formulated as aerosols and dry powders are also described.

HEXAHYDROBENZO(A)PHENANTHRIDINE COMPOUNDS

Trans-hexahydrobenzophenanthridines of the formula STR1 wherein R is hydrogen or C 1-C 4 alkyl; R 1 is hydrogen, benzoyl or pivaloyl; and x is hydrogen, chloro, bromo, iodo or a group of the formula OR 2, are novel ligands for dopamine receptors.